Annual Current Liabilities
$30.54 B
+$4.25 B+16.16%
31 December 2023
Summary:
AstraZeneca annual total current liabilities is currently $30.54 billion, with the most recent change of +$4.25 billion (+16.16%) on 31 December 2023. During the last 3 years, it has risen by +$10.23 billion (+50.40%). AZN annual current liabilities is now at all-time high.AZN Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Current Liabilities
$25.93 B
-$2.64 B-9.24%
30 September 2024
Summary:
AstraZeneca quarterly total current liabilities is currently $25.93 billion, with the most recent change of -$2.64 billion (-9.24%) on 30 September 2024. Over the past year, it has dropped by -$2.66 billion (-9.31%). AZN quarterly current liabilities is now -15.11% below its all-time high of $30.54 billion, reached on 31 December 2023.AZN Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AZN Current Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +16.2% | -9.3% |
| 3 y3 years | +50.4% | +9.6% |
| 5 y5 years | +87.5% | +75.5% |
AZN Current Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +50.4% | -15.1% | +18.8% |
| 5 y | 5 years | at high | +87.5% | -15.1% | +75.5% |
| alltime | all time | at high | +1789.5% | -15.1% | +774.6% |
AstraZeneca Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $25.93 B(-9.2%) |
| June 2024 | - | $28.57 B(-1.2%) |
| Mar 2024 | - | $28.90 B(-5.4%) |
| Dec 2023 | $30.54 B(+16.2%) | $30.54 B(+6.8%) |
| Sept 2023 | - | $28.59 B(+8.4%) |
| June 2023 | - | $26.38 B(+6.1%) |
| Mar 2023 | - | $24.86 B(-5.5%) |
| Dec 2022 | $26.29 B(+16.4%) | $26.29 B(+5.8%) |
| Sept 2022 | - | $24.85 B(+13.9%) |
| June 2022 | - | $21.82 B(-4.1%) |
| Mar 2022 | - | $22.74 B(+0.6%) |
| Dec 2021 | $22.59 B(+11.3%) | $22.59 B(-4.5%) |
| Sept 2021 | - | $23.65 B(+6.4%) |
| June 2021 | - | $22.22 B(+3.3%) |
| Mar 2021 | - | $21.51 B(+5.9%) |
| Dec 2020 | $20.31 B(+12.1%) | $20.31 B(+7.2%) |
| Sept 2020 | - | $18.94 B(+4.2%) |
| June 2020 | - | $18.18 B(+6.7%) |
| Mar 2020 | - | $17.04 B(-5.9%) |
| Dec 2019 | $18.12 B(+11.2%) | $18.12 B(+22.6%) |
| Sept 2019 | - | $14.78 B(-7.8%) |
| June 2019 | - | $16.03 B(-12.2%) |
| Mar 2019 | - | $18.26 B(+12.1%) |
| Dec 2018 | $16.29 B(-0.6%) | $16.29 B(+6.8%) |
| Sept 2018 | - | $15.25 B(-11.4%) |
| June 2018 | - | $17.20 B(-5.3%) |
| Mar 2018 | - | $18.16 B(+10.9%) |
| Dec 2017 | $16.38 B(+7.4%) | $16.38 B(+13.3%) |
| Sept 2017 | - | $14.46 B(-7.6%) |
| June 2017 | - | $15.66 B(+1.5%) |
| Mar 2017 | - | $15.43 B(+1.1%) |
| Dec 2016 | $15.26 B(+2.6%) | $15.26 B(-0.8%) |
| Sept 2016 | - | $15.38 B(+7.3%) |
| June 2016 | - | $14.34 B(-10.0%) |
| Mar 2016 | - | $15.93 B(+7.1%) |
| Dec 2015 | $14.87 B(-14.2%) | $14.87 B(-7.3%) |
| Sept 2015 | - | $16.04 B(-0.7%) |
| June 2015 | - | $16.15 B(+2.5%) |
| Mar 2015 | - | $15.76 B(-9.1%) |
| Dec 2014 | $17.33 B(+8.0%) | $17.33 B(+9.5%) |
| Sept 2014 | - | $15.82 B(-3.1%) |
| June 2014 | - | $16.32 B(-6.8%) |
| Mar 2014 | - | $17.51 B(+9.1%) |
| Dec 2013 | $16.05 B(+15.4%) | $16.05 B(+9.4%) |
| Sept 2013 | - | $14.68 B(-3.4%) |
| June 2013 | - | $15.20 B(+9.6%) |
| Mar 2013 | - | $13.86 B(-0.3%) |
| Dec 2012 | $13.90 B(-11.7%) | $13.90 B(-1.6%) |
| Sept 2012 | - | $14.13 B(-4.5%) |
| June 2012 | - | $14.80 B(-6.3%) |
| Mar 2012 | - | $15.80 B(+0.3%) |
| Dec 2011 | $15.75 B(-6.2%) | $15.75 B(+7.5%) |
| Sept 2011 | - | $14.66 B(+5.9%) |
| June 2011 | - | $13.84 B(-13.6%) |
| Mar 2011 | - | $16.02 B(-4.6%) |
| Dec 2010 | $16.79 B | $16.79 B(-0.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2010 | - | $16.85 B(+3.4%) |
| June 2010 | - | $16.30 B(-4.1%) |
| Mar 2010 | - | $16.99 B(-3.7%) |
| Dec 2009 | $17.64 B(+31.5%) | $17.64 B(+16.7%) |
| Sept 2009 | - | $15.12 B(-0.2%) |
| June 2009 | - | $15.14 B(+7.8%) |
| Mar 2009 | - | $14.05 B(+4.7%) |
| Dec 2008 | $13.41 B(-11.7%) | $13.41 B(-7.2%) |
| Sept 2008 | - | $14.46 B(-9.6%) |
| June 2008 | - | $15.99 B(+2.0%) |
| Mar 2008 | - | $15.68 B(+3.3%) |
| Dec 2007 | $15.19 B(+60.8%) | $15.19 B(-2.2%) |
| Sept 2007 | - | $15.53 B(-37.7%) |
| June 2007 | - | $24.93 B(+140.9%) |
| Mar 2007 | - | $10.35 B(+9.5%) |
| Dec 2006 | $9.45 B(+38.1%) | $9.45 B(+16.8%) |
| Sept 2006 | - | $8.09 B(-3.8%) |
| June 2006 | - | $8.40 B(-11.0%) |
| Mar 2006 | - | $9.45 B(+38.1%) |
| Dec 2005 | $6.84 B(+3.8%) | $6.84 B(+1.5%) |
| Sept 2005 | - | $6.74 B(-0.8%) |
| June 2005 | - | $6.80 B(-0.6%) |
| Mar 2005 | - | $6.84 B(+3.8%) |
| Dec 2004 | $6.59 B(-14.4%) | $6.59 B(-2.6%) |
| Sept 2004 | - | $6.76 B(-2.8%) |
| June 2004 | - | $6.96 B(-10.2%) |
| Mar 2004 | - | $7.75 B(+0.7%) |
| Dec 2003 | $7.70 B(-6.3%) | $7.70 B(+8.5%) |
| Sept 2003 | - | $7.09 B(-0.4%) |
| June 2003 | - | $7.12 B(-12.7%) |
| Mar 2003 | - | $8.16 B(-0.7%) |
| Dec 2002 | $8.21 B(+26.8%) | $8.21 B(+19.0%) |
| Sept 2002 | - | $6.90 B(-3.7%) |
| June 2002 | - | $7.16 B(-0.9%) |
| Mar 2002 | - | $7.23 B(+11.6%) |
| Dec 2001 | $6.48 B(-6.1%) | $6.48 B(+1.2%) |
| Sept 2001 | - | $6.40 B(+1.8%) |
| June 2001 | - | $6.29 B(-9.8%) |
| Mar 2001 | - | $6.97 B(+1.0%) |
| Dec 2000 | $6.90 B(-1.7%) | $6.90 B(-4.5%) |
| Sept 2000 | - | $7.22 B(+6.2%) |
| June 2000 | - | $6.80 B(-1.3%) |
| Mar 2000 | - | $6.89 B(-1.9%) |
| Dec 1999 | $7.02 B(+24.2%) | $7.02 B(+12.3%) |
| Sept 1999 | - | $6.25 B(+5.0%) |
| June 1999 | - | $5.95 B(+5.3%) |
| Dec 1998 | $5.65 B(+83.5%) | $5.65 B(+75.2%) |
| June 1998 | - | $3.23 B(+4.7%) |
| Dec 1997 | $3.08 B(-3.8%) | $3.08 B(-3.8%) |
| Dec 1996 | $3.20 B(+2.4%) | $3.20 B(+2.4%) |
| Dec 1995 | $3.13 B(+5.5%) | $3.13 B(+1.4%) |
| June 1995 | - | $3.09 B(+4.1%) |
| Dec 1994 | $2.96 B(-15.1%) | $2.96 B(-15.1%) |
| Dec 1993 | $3.49 B(-12.0%) | $3.49 B |
| Dec 1992 | $3.97 B(+129.3%) | - |
| Dec 1991 | $1.73 B(+7.1%) | - |
| Dec 1990 | $1.62 B | - |
FAQ
- What is AstraZeneca annual total current liabilities?
- What is the all time high annual current liabilities for AstraZeneca?
- What is AstraZeneca annual current liabilities year-on-year change?
- What is AstraZeneca quarterly total current liabilities?
- What is the all time high quarterly current liabilities for AstraZeneca?
- What is AstraZeneca quarterly current liabilities year-on-year change?
What is AstraZeneca annual total current liabilities?
The current annual current liabilities of AZN is $30.54 B
What is the all time high annual current liabilities for AstraZeneca?
AstraZeneca all-time high annual total current liabilities is $30.54 B
What is AstraZeneca annual current liabilities year-on-year change?
Over the past year, AZN annual total current liabilities has changed by +$4.25 B (+16.16%)
What is AstraZeneca quarterly total current liabilities?
The current quarterly current liabilities of AZN is $25.93 B
What is the all time high quarterly current liabilities for AstraZeneca?
AstraZeneca all-time high quarterly total current liabilities is $30.54 B
What is AstraZeneca quarterly current liabilities year-on-year change?
Over the past year, AZN quarterly total current liabilities has changed by -$2.66 B (-9.31%)